About Neurocrine Biosciences, Inc. - Common Stock Company overview from Wikipedia

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

NBIX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price

$155.47

Market Cap

$15.56B

P/E (TTM)

33.3

EPS (TTM)

$4.67

Revenue (TTM)

$2.86B

Div Yield

—

ROE

16.1%

Debt/Equity

—

52W Range

$123 – $186

NBIX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $2.86B

2016-12-31 → 2025-12-31

EPS $4.67

2016-12-31 → 2025-12-31

Free Cash Flow $749M

2016-12-31 → 2025-12-31

Margins 16.7%

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric

5Y trend

NBIX

Peer Median

P/E (TTM)

33.3

16.9

P/S (TTM)

5.4

9.6

P/B

4.8

7.7

Price / FCF

20.8

—

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric

5Y trend

NBIX

Peer Median

Operating Margin

21.6%

—

Net Profit Margin

16.7%

-36.9%

ROA

11.5%

-21.8%

ROE

16.1%

-47.3%

ROIC

12.9%

—

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric

5Y trend

NBIX

Peer Median

Current Ratio

3.4

3.5

Quick Ratio

1.9

—

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric

5Y trend

NBIX

Peer Median

Revenue YoY

21.4%

—

Revenue CAGR 3Y

24.3%

—

Revenue CAGR 5Y

22.3%

—

EPS YoY

41.9%

—

Net Income YoY

40.2%

—

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric

5Y trend

NBIX

Peer Median

EPS (Diluted)

$4.67

—

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric

5Y trend

NBIX

Peer Median

NBIX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

BUY 36 analysts

Strong Buy 14 38.9%
Buy 17 47.2%
Hold 5 13.9%
Sell 0 0.0%
Strong Sell 0 0.0%

12-Month Price Target

27 analysts · 2026-08-15

Median $215.00

← Below all targets $155.47

Low $165.00

High $249.00

Median target $215.00 +38.3%

Mean target $211.57 +36.1%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise

0.24%

Period	EPS Actual	EPS Est	Surprise
June 30, 2026	$1.39	$1.37	0.02%
March 31, 2026	$1.91	$1.20	0.71%
Dec. 31, 2025	$1.91	$1.20	0.71%
Sept. 30, 2025	$2.04	$1.62	0.42%
June 30, 2025	$1.06	$0.99	0.07%
March 31, 2025	$0.08	$0.56	-0.48%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker	Market Cap	P/E	Rev YoY	Net Margin	ROE	Gross Margin
NBIX	$14.20B	30.4	21.4%	16.7%	16.1%	—
INCY	$19.60B	15.4	21.2%	25.0%	27.6%	—
MRNA	$11.62B	-4.1	-39.9%	-145.2%	-31.3%	—
UTHR	$21.27B	17.5	10.6%	41.9%	18.7%	87.9%
BBIO	$14.90B	-20.2	126.3%	-146.0%	41.2%	—
BMRN	$11.43B	33.0	12.9%	10.8%	5.8%	—
EXEL	$11.44B	15.7	7.0%	33.7%	37.3%	—
ARWR	$4.68B	-3449.0	23258.2%	-0.20%	-0.50%	—
MDGL	$13.30B	-45.3	432.1%	-30.1%	-44.4%	—
HALO	$7.93B	26.3	37.5%	22.7%	166.1%	—

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 17

Annual Income Statement data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$2.86B	$2.36B	$1.89B	$1.49B	$1.13B	$1.05B	$788M	$451M	$162M	$15M	$20M	$0
Cost of Revenue	$52M	$34M	$40M	$23M	$14M	$10M	·	$5M	$1M	$0	$0	·
R&D Expense	·	·	·	·	·	·	·	$161M	$122M	$94M	$81M	$46M
SG&A Expense	$1.16B	$1.01B	$888M	$753M	$583M	$433M	$354M	$249M	$170M	$68M	$32M	$18M
Operating Expenses	$2.24B	$1.78B	$1.64B	$1.24B	$1.03B	$883M	$716M	$414M	$293M	$162M	$114M	$64M
Operating Income	$619M	$570M	$251M	$249M	$102M	$163M	$72M	$37M	$-131M	$-147M	$-94M	$-64M
Interest Expense	·	·	$5M	$7M	$26M	$33M	$32M	$30M	$20M	$0	$0	·
Interest Income	·	·	·	·	·	·	·	·	·	$3M	$2M	$629.0K
Other Non-op	$86M	$-84M	$81M	$-35M	$-1M	$-56M	$-26M	$-15M	$-11M	$6M	$20.0K	$18.0K
Pretax Income	$705M	$486M	$332M	$214M	$101M	$107M	$46M	$22M	$-143M	$-141M	·	·
Income Tax	$227M	$145M	$82M	$59M	$12M	$-301M	$10M	$700.0K	$0	$0	$0	$0
Net Income	$479M	$341M	$250M	$154M	$90M	$407M	$37M	$21M	$-143M	$-141M	$-89M	$-61M
EPS (Basic)	$4.81	$3.40	$2.56	$1.61	$0.95	$4.38	$0.40	$0.23	$-1.62	$-1.63	$-1.05	$-0.81
EPS (Diluted)	$4.67	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.22	$-1.62	$-1.63	$-1.05	$-0.81
Shares (Basic)	99,500,000	100,400,000	97,700,000	95,800,000	94,600,000	93,100,000	91,600,000	90,200,000	88,089,000	86,713,000	84,496,000	74,577,000
Shares (Diluted)	102,500,000	103,700,000	101,000,000	98,900,000	97,900,000	97,800,000	95,700,000	95,400,000	88,089,000	86,713,000	84,496,000	74,577,000
EBITDA	$619M	$570M	$251M	$249M	$102M	$163M	$72M	$37M	$-131M	$-147M	·	$-64M

Balance Sheet 28

Annual Balance Sheet data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$713M	$233M	$251M	$263M	$341M	$187M	$112M	$142M	$255M	$83M	$74M	$31M
Short-term Investments	·	·	·	·	$370M	$614M	$558M	$509M	$261M	$224M	$305M	$163M
Receivables	$687M	$479M	$439M	$350M	$186M	$157M	$127M	$57M	$31M	$0	·	·
Inventory	$69M	$57M	$38M	$35M	$30M	$28M	$17M	$11M	$1M	$0	·	·
Prepaid Expense	$171M	$48M	·	·	·	·	·	·	·	·	·	·
Other Current Assets	$116M	$64M	$98M	$79M	$46M	$30M	$17M	$19M	$7M	$3M	$5M	$4M
Current Assets	$2.52B	$1.72B	$1.61B	$1.45B	$973M	$1.02B	$831M	$738M	$555M	$310M	$384M	$198M
PP&E (Net)	$90M	$83M	$71M	$59M	$59M	$45M	$42M	$34M	$11M	$6M	$3M	$3M
PP&E (Gross)	$208M	$189M	$154M	$125M	$110M	$86M	$76M	$62M	$38M	$32M	$30M	$31M
Accum. Depreciation	$118M	$106M	$83M	$66M	$52M	$42M	$34M	$28M	$28M	$26M	$27M	$29M
Goodwill	$6M	$6M	$6M	$5M	$0	·	·	·	·	·	·	·
Intangibles	$5M	$36M	$36M	$37M	$0	·	·	·	·	·	·	·
Other Non-current Assets	$49M	$52M	$50M	$25M	$4M	$6M	$0	·	·	·	·	·
Total Assets	$4.63B	$3.72B	$3.25B	$2.37B	$2.07B	$1.73B	$1.31B	$993M	$818M	$365M	$475M	$243M
Accounts Payable	$674M	$462M	$449M	$348M	$226M	$169M	$141M	$86M	$6M	$5M	$3M	$246.0K
Accrued Liabilities	·	·	·	·	·	·	·	·	·	$21M	$19M	$12M
Current Liabilities	$743M	$508M	$655M	$538M	$246M	$186M	$565M	$88M	$54M	$30M	$26M	$16M
Capital Leases	$415M	$455M	$258M	$94M	$105M	$94M	$87M	$0	·	·	·	·
Deferred Tax	$0	·	·	·	·	·	·	·	·	·	·	·
Other Non-current Liabilities	$220M	$166M	$106M	$30M	$12M	$10M	$17M	$36M	$0	$113.0K	$221.0K	$260.0K
Total Liabilities	$1.38B	$1.13B	$1.02B	$661M	$698M	$608M	$669M	$512M	$445M	$50M	$50M	$34M
Common Stock	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$91.0K	$89.0K	$87.0K	$86.0K	$76.0K
Paid-in Capital	·	·	·	·	·	·	·	·	·	·	·	$1.04B
Retained Earnings	$448M	$29M	$-157M	$-407M	$-636M	$-725M	$-1.13B	$-1.18B	$-1.20B	$-1.06B	$-915M	$-826M
AOCI	$13M	$6M	$7M	$-8M	$-2M	$2M	$1M	$-2M	$-2M	$-318.0K	$-977.0K	$-277.0K
Stockholders' Equity	$3.25B	$2.59B	$2.23B	$1.71B	$1.37B	$1.13B	$637M	$481M	$372M	$315M	$424M	$209M
Liabilities + Equity	$4.63B	$3.72B	$3.25B	$2.37B	$2.07B	$1.73B	$1.31B	$993M	$818M	$365M	$475M	$243M
Shares Outstanding	100,100,000	99,400,000	98,700,000	96,500,000	94,900,000	93,500,000	92,300,000	90,797,000	88,793,903	86,883,300	86,262,594	76,465,942

Cash Flow 15

Annual Cash Flow data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
D&A	·	·	·	·	·	·	·	$4M	$2M	$1M	$1M	$827.0K
Stock-based Comp	$218M	$196M	$194M	$173M	$134M	$100M	$75M	$58M	$43M	$28M	$28M	$10M
Deferred Tax	$164M	$-123M	$-61M	$22M	$6M	$-311M	$0	$0	·	·	·	·
Amort. of Intangibles	$4M	$4M	$4M	$500.0K	$0	$0	·	·	·	·	·	·
Operating Cash Flow	$783M	$595M	$390M	$339M	$256M	$228M	$147M	$101M	$-94M	$-106M	$-38M	$-47M
CapEx	$34M	$38M	$28M	$16M	$23M	$11M	$15M	$25M	$7M	$4M	$2M	$2M
Investing Cash Flow	$-264M	$-127M	$-467M	$-177M	$-130M	$4M	$-211M	$-243M	$-251M	$113M	·	·
Stock Issued	$129M	$122M	$65M	$45M	$28M	$29M	$32M	$30M	$14M	$2M	$277M	$139M
Stock Repurchased	$168M	$300M	$0	$0	·	·	·	·	·	·	·	·
Net Stock Activity	$-38M	$-178M	$65M	$45M	$28M	$29M	$27M	$30M	$14M	$2M	·	$139M
Financing Cash Flow	$-38M	$-487M	$65M	$-234M	$27M	$-158M	$32M	$30M	$517M	$2M	·	·
Net Change in Cash	$480M	$-18M	$-12M	$-73M	$154M	$75M	$-32M	$-112M	$171M	$9M	$43M	$-14M
Taxes Paid	$81M	·	·	·	·	·	·	·	·	·	·	·
Free Cash Flow	$749M	$557M	$362M	$323M	$233M	$218M	$137M	$77M	$-101M	$-110M	·	$-49M
Levered FCF	·	·	$358M	$318M	$210M	$92M	$112M	$47M	·	·	·	·

Profitability 7

Annual Profitability data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Operating Margin	21.6%	24.2%	13.3%	16.7%	9.0%	15.6%	9.2%	8.2%	-81.3%	-982.5%	·	·
Net Margin	16.7%	14.5%	13.2%	10.4%	7.9%	38.9%	4.7%	4.7%	-88.2%	-940.6%	·	·
Pretax Margin	24.7%	20.6%	17.6%	14.4%	8.9%	10.2%	5.9%	4.8%	·	·	·	·
EBITDA Margin	21.6%	24.2%	13.3%	16.7%	9.0%	15.6%	9.2%	8.2%	-81.3%	-982.5%	·	·
ROA	11.5%	9.8%	8.9%	7.0%	4.7%	26.8%	3.2%	2.3%	-24.1%	-33.6%	·	-30.4%
ROE	16.1%	12.9%	11.8%	9.5%	6.6%	42.2%	6.1%	4.5%	-41.5%	-38.2%	·	-36.8%
ROIC	12.9%	15.5%	8.5%	10.5%	6.6%	55.2%	9.0%	7.4%	·	·	·	·

Liquidity & Solvency 3

Annual Liquidity & Solvency data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	3.4	3.4	2.5	2.7	4.0	5.4	1.5	8.4	10.2	10.2	·	12.7
Quick Ratio	1.9	1.4	1.1	1.1	3.6	5.1	1.4	2.2	10.1	10.1	·	12.4
Interest Coverage	·	·	54.5	35.1	4.0	5.0	2.3	1.2	-6.7	·	·	·

Efficiency 3

Annual Efficiency data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.7	0.7	0.7	0.7	0.6	0.7	0.7	0.5	0.3	0.0	·	0.0
Inventory Turnover	0.8	0.7	1.1	0.7	·	·	·	0.8	·	·	·	·
Receivables Turnover	4.9	5.1	4.8	5.6	6.6	7.4	8.6	10.3	10.4	·	·	·

Per Share 5

Annual Per Share data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$32.50	$26.05	$22.61	$17.70	$14.48	$12.04	$6.90	$5.29	$4.19	$3.62	·	$2.73
Revenue / Share	$27.91	$22.71	$18.68	$15.05	$11.58	$10.69	$8.23	$4.73	$1.83	$0.17	·	$0.00
Cash Flow / Share	$7.64	$5.74	$3.86	$3.43	$2.62	$2.34	$1.59	$1.06	$-1.07	$-1.22	·	$-0.63
Cash / Share	$7.12	$2.34	$2.54	$2.72	$3.59	$2.00	$1.22	$1.56	$2.87	$0.96	·	$0.41
EPS (TTM)	$4.67	$3.29	$2.47	$1.56	$0.92	$4.16	$0.39	$0.22	$-1.62	$-1.63	$-1.05	$-0.81

Growth Rates 9

Annual Growth Rates data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	21.4%	24.8%	26.8%	31.3%	8.4%	·	·	·	·	·	·	·
Revenue CAGR 3Y	24.3%	27.6%	21.7%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	22.3%	·	·	·	·	·	·	·	·	·	·	·
EPS YoY	41.9%	33.2%	58.3%	69.6%	-77.9%	·	·	·	·	·	·	·
EPS CAGR 3Y	44.1%	52.9%	-16.0%	·	·	·	·	·	·	·	·	·
EPS CAGR 5Y	2.3%	·	·	·	·	·	·	·	·	·	·	·
Net Income YoY	40.2%	36.7%	61.6%	72.4%	-78.0%	·	·	·	·	·	·	·
Net Income CAGR 3Y	45.8%	56.2%	-15.0%	·	·	·	·	·	·	·	·	·
Net Income CAGR 5Y	3.3%	·	·	·	·	·	·	·	·	·	·	·

Valuation (TTM) 10

Annual Valuation (TTM) data for NBIX
Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$2.86B	$2.36B	$1.89B	$1.49B	$1.13B	$1.05B	$788M	$451M	$162M	$15M	$20M	$0
Net Income TTM	$479M	$341M	$250M	$154M	$90M	$407M	$37M	$21M	$-143M	$-141M	$-89M	$-61M
Market Cap	$14.20B	$13.57B	$13.00B	$11.53B	$8.08B	$8.96B	$9.92B	$6.48B	$6.89B	$3.36B	·	$1.71B
P/E	30.4	41.5	53.3	76.6	92.6	23.0	275.6	324.6	-47.9	-23.7	-53.9	-27.6
P/S	5.0	5.8	6.9	7.7	7.1	8.6	12.6	14.4	42.6	224.2	·	·
P/B	4.4	5.2	5.8	6.7	5.9	8.0	15.6	13.5	18.5	10.7	·	8.2
P / Tangible Book	4.4	5.3	5.9	6.9	5.9	8.0	·	·	·	·	·	·
P / Cash Flow	18.1	22.8	33.4	34.0	31.5	39.2	65.2	64.0	-73.0	-31.7	·	-36.2
P / FCF	19.0	24.4	36.0	35.7	34.7	41.2	72.2	84.7	-68.0	-30.5	·	-35.0
Earnings Yield	3.3%	2.4%	1.9%	1.3%	1.1%	4.3%	0.36%	0.31%	-2.1%	-4.2%	-1.9%	-3.6%

Income Statement 15

Quarterly Income Statement data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$959M	$814M	$806M	$795M	$688M	$573M	$628M	$622M	$590M	$515M	$515M	$499M	$453M	$420M	$412M	$388M
Cost of Revenue	·	$14M	$18M	$14M	$11M	$9M	$9M	$8M	$9M	$8M	$8M	$11M	$12M	$8M	$8M	$6M
SG&A Expense	$440M	$318M	$302M	$292M	$286M	$276M	$288M	$234M	$242M	$243M	$219M	$204M	$222M	$243M	$183M	$186M
Operating Expenses	$808M	$621M	$595M	$556M	$542M	$549M	$486M	$438M	$445M	$416M	$365M	$358M	$379M	$535M	$309M	$300M
Operating Income	$152M	$193M	$211M	$239M	$146M	$24M	$142M	$184M	$145M	$99M	$150M	$141M	$74M	$-114M	$103M	$88M
Interest Expense	·	·	·	·	·	·	·	·	·	$1M	·	$1M	$1M	$1M	·	$1M
Other Non-op	$11M	$53M	$28M	$53M	$14M	$-9M	$21M	$6M	$-47M	$-65M	$48M	$-26M	$48M	$11M	$14M	$10M
Pretax Income	$162M	$247M	$239M	$292M	$160M	$15M	$163M	$190M	$99M	$34M	$198M	$116M	$122M	$-103M	$118M	$98M
Income Tax	$18M	$49M	$86M	$82M	$52M	$7M	$60M	$60M	$34M	$-9M	$50M	$32M	$26M	$-27M	$29M	$29M
Net Income	$144M	$198M	$154M	$210M	$108M	$8M	$103M	$130M	$65M	$43M	$148M	$83M	$96M	$-77M	$89M	$68M
EPS (Basic)	$1.43	$1.97	$1.53	$2.11	$1.09	$0.08	$1.05	$1.28	$0.64	$0.43	$1.52	$0.85	$0.98	$-0.79	$0.92	$0.72
EPS (Diluted)	$1.39	$1.91	$1.49	$2.04	$1.06	$0.08	$1.00	$1.24	$0.63	$0.42	$1.49	$0.82	$0.95	$-0.79	$0.91	$0.69
Shares (Basic)	101,000,000	100,500,000	-198,600,000	99,400,000	99,000,000	99,700,000	-201,300,000	101,100,000	100,800,000	99,800,000	-194,900,000	97,900,000	97,600,000	97,100,000	-190,900,000	95,800,000
Shares (Diluted)	104,200,000	103,400,000	-203,500,000	102,500,000	101,000,000	102,500,000	-208,100,000	104,300,000	103,900,000	103,600,000	-197,400,000	101,100,000	100,200,000	97,100,000	-193,300,000	99,000,000
EBITDA	$152M	$193M	·	$239M	$146M	$24M	·	$184M	$145M	$99M	·	$141M	$74M	$-114M	·	$88M

Balance Sheet 25

Quarterly Balance Sheet data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$332M	$266M	$713M	$340M	$264M	$194M	$233M	$349M	$140M	$396M	·	$294M	$160M	$104M	·	$212M
Receivables	$887M	$768M	$687M	$728M	$596M	$516M	$479M	$481M	$468M	$451M	·	$418M	$388M	$392M	·	$301M
Inventory	$104M	$64M	$69M	$69M	$57M	$59M	$57M	$46M	$42M	$37M	·	$29M	$32M	$33M	·	$37M
Prepaid Expense	$217M	$225M	$171M	$178M	·	·	$48M	·	·	·	·	·	·	·	·	·
Other Current Assets	$39M	$62M	$116M	$68M	$121M	$119M	$64M	$122M	$120M	$100M	·	$108M	$101M	$113M	·	$68M
Current Assets	$1.64B	$2.44B	$2.52B	$2.16B	$1.75B	$1.64B	$1.72B	$1.88B	$1.67B	$1.80B	·	$1.65B	$1.50B	$1.43B	·	$1.21B
PP&E (Net)	$90M	$91M	$90M	$97M	$92M	$87M	$83M	$80M	$80M	$75M	·	$69M	$66M	$63M	·	$61M
PP&E (Gross)	·	·	$208M	·	·	·	$189M	·	·	·	·	·	·	·	·	·
Accum. Depreciation	·	·	$118M	·	·	·	$106M	·	·	·	·	·	·	·	·	·
Goodwill	$501M	·	·	·	·	·	·	$6M	$6M	$6M	·	$6M	$6M	$6M	$5M	·
Intangibles	$2.23B	·	·	$36M	$37M	$36M	·	$34M	$34M	$34M	·	$35M	$37M	$37M	·	·
Other Non-current Assets	$59M	$74M	$60M	$20M	$22M	$15M	$52M	$62M	$58M	$51M	·	$43M	$36M	$25M	·	$10M
Total Assets	$5.36B	$4.91B	$4.63B	$4.27B	$3.89B	$3.69B	$3.72B	$3.54B	$3.31B	$3.47B	·	$2.85B	$2.61B	$2.36B	·	$2.14B
Accounts Payable	$808M	$773M	$674M	$584M	$490M	$475M	$462M	$393M	$358M	$417M	·	$503M	$392M	$356M	·	$298M
Current Liabilities	$874M	$832M	$743M	$638M	$546M	$523M	$508M	$430M	$398M	$713M	·	$692M	$582M	$374M	·	$485M
Capital Leases	$402M	$406M	$415M	$428M	$439M	$448M	$455M	$251M	$256M	$253M	·	$86M	$89M	$90M	·	$97M
Deferred Tax	$92M	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Other Non-current Liabilities	$298M	$261M	$220M	$196M	$210M	$182M	$166M	$135M	$141M	$120M	·	$69M	$88M	$41M	·	$17M
Total Liabilities	$1.67B	$1.50B	$1.38B	$1.26B	$1.20B	$1.15B	$1.13B	$816M	$796M	$1.09B	·	$846M	$760M	$675M	·	$599M
Common Stock	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	$100.0K	·	$100.0K	$100.0K	$100.0K	·	$100.0K
Retained Earnings	$724M	$590M	$448M	$294M	$84M	$-5M	$29M	$81M	$-49M	$-114M	·	$-305M	$-388M	$-483M	·	$-496M
AOCI	$5M	$400.0K	$13M	$13M	$12M	$9M	$6M	$14M	$2M	$3M	·	$-2M	$-1M	$-3M	·	$-14M
Stockholders' Equity	$3.69B	$3.41B	$3.25B	$3.00B	$2.69B	$2.54B	$2.59B	$2.72B	$2.51B	$2.39B	$2.23B	$2.00B	$1.85B	$1.68B	$1.71B	$1.54B
Liabilities + Equity	$5.36B	$4.91B	$4.63B	$4.27B	$3.89B	$3.69B	$3.72B	$3.54B	$3.31B	$3.47B	·	$2.85B	$2.61B	$2.36B	·	$2.14B
Shares Outstanding	101,600,000	100,600,000	100,100,000	99,700,000	99,000,000	99,000,000	99,400,000	101,200,000	100,900,000	100,600,000	·	98,200,000	97,600,000	97,500,000	·	96,100,000

Cash Flow 12

Quarterly Cash Flow data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Stock-based Comp	$65M	$57M	$59M	$54M	$53M	$53M	$66M	$42M	$43M	$44M	$38M	$48M	$68M	$40M	$44M	$43M
Amort. of Intangibles	$16M	$100.0K	$1M	$1M	$1M	$1M	$900.0K	$900.0K	$900.0K	$900.0K	$800.0K	$900.0K	$900.0K	$900.0K	$500.0K	$0
Operating Cash Flow	$136M	$146M	$388M	$228M	$102M	$65M	$242M	$158M	$65M	$130M	$124M	$212M	$180M	$-125M	$143M	$99M
CapEx	$8M	$9M	$-2M	$13M	$12M	$11M	$7M	$8M	$12M	$11M	$5M	$8M	$7M	$8M	$2M	$-2M
Investing Cash Flow	$-135M	$-506M	$-53M	$-197M	$-29M	$14M	$-68M	$25M	$-28M	$-55M	$-202M	$-97M	$-126M	$-42M	$-116M	$-61M
Stock Issued	$85M	$24M	$37M	$46M	$14M	$32M	$10M	$26M	$16M	$70M	$35M	$19M	$3M	$8M	$25M	$11M
Stock Repurchased	$12M	$54M	$0	$0	$18M	$150M	$300M	$0	$0	$0	·	·	·	·	·	·
Net Stock Activity	·	$-30M	·	·	·	$-118M	·	·	·	$70M	·	·	·	$8M	·	·
Financing Cash Flow	$63M	$-86M	$37M	$46M	$-3M	$-118M	$-290M	$26M	$-293M	$70M	$35M	$19M	$3M	$8M	$25M	$11M
Net Change in Cash	$64M	$-446M	$373M	$76M	$70M	$-39M	$-116M	$209M	$-257M	$145M	$-43M	$134M	$57M	$-159M	$51M	$49M
Free Cash Flow	·	$137M	·	·	·	$54M	·	·	·	$119M	·	·	·	$-134M	·	·
Levered FCF	·	·	·	·	·	·	·	·	·	$118M	·	·	·	$-135M	·	·

Profitability 7

Quarterly Profitability data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Operating Margin	15.8%	23.7%	·	30.1%	21.2%	4.1%	·	29.5%	24.6%	19.3%	·	28.3%	16.3%	-27.2%	·	22.6%
Net Margin	15.1%	24.3%	·	26.4%	15.6%	1.4%	·	20.9%	11.0%	8.4%	·	16.7%	21.1%	-18.2%	·	17.7%
Pretax Margin	16.9%	30.3%	·	36.7%	23.2%	2.6%	·	30.6%	16.7%	6.7%	·	23.2%	26.9%	-24.6%	·	25.2%
EBITDA Margin	15.8%	23.7%	·	30.1%	21.2%	4.1%	·	29.5%	24.6%	19.3%	·	28.3%	16.3%	-27.2%	·	22.6%
ROA	3.1%	4.6%	·	5.4%	3.0%	0.22%	·	4.1%	2.2%	1.5%	·	3.3%	4.1%	-3.4%	·	3.3%
ROE	4.5%	6.7%	·	7.3%	4.1%	0.32%	·	5.5%	3.0%	2.1%	·	4.7%	5.8%	-5.0%	·	4.7%
ROIC	3.6%	4.5%	·	5.7%	3.6%	0.50%	·	4.6%	3.8%	5.2%	·	5.1%	3.1%	-5.0%	·	4.0%

Liquidity & Solvency 3

Quarterly Liquidity & Solvency data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	1.9	2.9	·	3.4	3.2	3.1	·	4.4	4.2	2.5	·	2.4	2.6	3.8	·	2.5
Quick Ratio	1.4	1.2	·	1.7	1.6	1.4	·	1.9	1.5	1.2	·	1.0	0.9	1.3	·	1.1
Interest Coverage	·	·	·	·	·	·	·	·	·	90.3	·	128.4	56.6	-103.8	·	73.2

Efficiency 3

Quarterly Efficiency data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2
Inventory Turnover	·	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.3	0.4	0.3	·	0.2
Receivables Turnover	1.3	1.3	·	1.3	1.3	1.2	·	1.4	1.4	1.2	·	1.4	1.4	1.3	·	1.7

Per Share 5

Quarterly Per Share data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$36.35	$33.87	·	$30.13	$27.22	$25.61	·	$26.87	$24.87	$23.72	·	$20.39	$18.99	$17.28	·	$16.07
Revenue / Share	$9.20	$7.88	·	$7.76	$6.81	$5.59	·	$5.96	$5.68	$4.97	·	$4.93	$4.52	$4.33	·	$3.92
Cash Flow / Share	·	$1.41	·	·	·	$0.63	·	·	·	$1.26	·	·	·	$-1.29	·	·
Cash / Share	$3.27	$2.65	·	$3.41	$2.67	$1.96	·	$3.45	$1.38	$3.94	·	$2.99	$1.64	$1.06	·	$2.21
EPS (TTM)	$6.40	$5.09	·	$4.42	$3.01	$2.37	·	$3.11	$2.82	$1.40	·	$1.67	$0.67	$-0.14	·	$0.88

Valuation (TTM) 10

Quarterly Valuation (TTM) data for NBIX
Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$3.26B	$2.87B	·	$2.68B	$2.47B	$2.30B	·	$2.23B	$2.06B	$1.89B	·	$1.76B	$1.64B	$1.50B	·	$1.37B
Net Income TTM	$659M	$523M	·	$455M	$310M	$246M	·	$321M	$287M	$145M	·	$170M	$70M	$-11M	·	$88M
Market Cap	$17.12B	$13.25B	·	$14.00B	$12.44B	$10.95B	·	$11.66B	$13.89B	$13.87B	·	$11.05B	$9.20B	$9.87B	·	$10.21B
P/E	26.3	25.9	·	31.8	41.8	46.7	·	37.0	48.8	98.5	·	67.4	140.7	-723.0	·	120.7
P/S	5.3	4.6	·	5.2	5.0	4.8	·	5.2	6.8	7.4	·	6.3	5.6	6.6	·	7.4
P/B	4.6	3.9	·	4.7	4.6	4.3	·	4.3	5.5	5.8	·	5.5	5.0	5.9	·	6.6
P / Tangible Book	17.7	3.9	·	4.7	4.7	4.4	·	4.4	5.6	5.9	·	5.6	5.1	6.0	·	6.6
P / Cash Flow	·	90.9	·	·	·	169.0	·	·	·	106.5	·	·	·	-78.8	·	·
P / FCF	·	96.9	·	·	·	202.4	·	·	·	116.5	·	·	·	-73.8	·	·
Earnings Yield	3.8%	3.9%	·	3.1%	2.4%	2.1%	·	2.7%	2.1%	1.0%	·	1.5%	0.71%	-0.14%	·	0.83%

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	$2.86B	$2.36B	$1.89B	$1.49B	$1.13B
Operating Margin %	21.6%	24.2%	13.3%	16.7%	9.0%
Net Income	$479M	$341M	$250M	$154M	$90M
Diluted EPS	$4.67	$3.29	$2.47	$1.56	$0.92

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Current Ratio	3.4	3.4	2.5	2.7	4.0
Quick Ratio	1.9	1.4	1.1	1.1	3.6

Cash Flow

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Free Cash Flow	$749M	$557M	$362M	$323M	$233M

Latest News Recent headlines mentioning this company

December 2027 Options Now Available For Neurocrine Biosciences (NBIX) Nasdaq · 4 months, 1 week ago
Stock Market Today, April 6: Soleno Therapeutics Climbs After $2.9 Billion All-Cash Buyout Agreement Nasdaq · 4 months, 1 week ago
Neurocrine To Acquire Soleno For $2.9 Bln Cash Deal; Soleno Stock Surges In Pre-market Nasdaq · 4 months, 1 week ago

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 827 filers · $10.1B total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter

New positions	Exited positions	Increased	Decreased	Net shares change
153 (+61 vs prior Q)	62 (-37 vs prior Q)	300 (+11 vs prior Q)	223 (+8 vs prior Q)	+9.4M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution	Value	Shares	% of tracked 13F	Type
Dodge & Cox	$941,218,594	5,584,707	9.32%	Shares
VANGUARD PORTFOLIO MANAGEMENT LLC	$838,307,078	4,974,083	8.30%	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$766,048,708	4,545,339	7.59%	Shares
STATE STREET CORP	$739,126,759	4,385,598	7.32%	Shares
RENAISSANCE TECHNOLOGIES LLC	$393,680,402	2,335,897	3.90%	Shares
TWO SIGMA INVESTMENTS, LP	$349,922,479	2,076,260	3.47%	Shares
Vestal Point Capital, LP	$316,845,800	1,880,000	3.14%	Shares
GEODE CAPITAL MANAGEMENT, LLC	$294,151,210	1,750,392	2.91%	Shares
RTW INVESTMENTS, LP	$213,689,740	1,267,925	2.12%	Shares
NORGES BANK	$164,132,866	973,880	1.63%	Shares
FIRST TRUST ADVISORS LP	$155,578,851	923,125	1.54%	Shares
JACOBS LEVY EQUITY MANAGEMENT, INC	$122,375,286	726,112	1.21%	Shares
TWO SIGMA ADVISERS, LP	$119,504,823	842,592	1.18%	Shares
Swedbank AB	$109,730,107	651,082	1.09%	Shares
VANGUARD FIDUCIARY TRUST CO	$109,170,737	647,763	1.08%	Shares
DIMENSIONAL FUND ADVISORS LP	$109,070,816	647,171	1.08%	Shares
VICTORY CAPITAL MANAGEMENT INC	$104,238,729	618,499	1.03%	Shares
Caisse de depot et placement du Quebec	$91,002,327	539,961	0.90%	Shares
ARMISTICE CAPITAL, LLC	$90,307,457	535,838	0.89%	Shares
PRIMECAP MANAGEMENT CO/CA/	$82,807,988	491,340	0.82%	Shares
AMERIPRISE FINANCIAL INC	$79,666,260	472,708	0.79%	Shares
Hood River Capital Management LLC	$79,082,184	469,233	0.78%	Shares
ROYAL BANK OF CANADA	$73,348,000	435,207	0.73%	Shares
Pictet Asset Management Holding SA	$72,751,030	430,635	0.72%	Shares
Gotham Asset Management, LLC	$62,622,213	371,568	0.62%	Shares
Fiera Capital Corp	$61,558,083	365,254	0.61%	Shares
BlackRock, Inc.	$61,129,161	362,709	0.61%	Shares
ALLIANCEBERNSTEIN L.P.	$60,767,710	461,270	0.60%	Shares
Vinva Investment Management Ltd	$58,838,530	346,109	0.58%	Shares
AustralianSuper Pty Ltd	$58,817,535	348,993	0.58%	Shares
GOLDMAN SACHS GROUP INC	$58,206,259	345,366	0.58%	Shares
BRAIDWELL LP	$56,656,579	336,171	0.56%	Shares
RHUMBLINE ADVISERS	$52,723,054	312,832	0.52%	Shares
Clearbridge Investments, LLC	$47,391,031	281,194	0.47%	Shares
SEIZERT CAPITAL PARTNERS, LLC	$46,740,991	277,337	0.46%	Shares
Swiss National Bank	$45,319,062	268,900	0.45%	Shares
BARCLAYS PLC	$44,228,304	262,428	0.44%	Shares
ENVESTNET ASSET MANAGEMENT INC	$44,187,600	262,192	0.44%	Shares
WORLDQUANT MILLENNIUM ADVISORS LLC	$44,038,027	261,299	0.44%	Shares
Candriam S.C.A.	$43,932,854	260,926	0.44%	Shares
BNP PARIBAS FINANCIAL MARKETS	$43,921,064	260,605	0.43%	Shares
FMR LLC	$40,551,501	240,612	0.40%	Shares
PRINCIPAL FINANCIAL GROUP INC	$40,285,595	239,034	0.40%	Shares
California Public Employees Retirement System	$39,090,345	231,942	0.39%	Shares
RENAISSANCE GROUP LLC	$38,589,515	228,970	0.38%	Shares
Assenagon Asset Management S.A.	$37,516,902	222,606	0.37%	Shares
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$37,508,000	222,554	0.37%	Shares
Sumitomo Mitsui Trust Group, Inc.	$36,317,270	215,488	0.36%	Shares
Carmignac Gestion	$36,083,344	214,100	0.36%	Shares
PFM Health Sciences, LP	$35,966,549	213,407	0.36%	Shares
Bridgewater Associates, LP	$34,663,773	205,677	0.34%	Shares
LOS ANGELES CAPITAL MANAGEMENT LLC	$34,304,966	203,548	0.34%	Shares
Nantahala Capital Management, LLC	$33,707,000	200,000	0.33%	Call option
BANK OF AMERICA CORP /DE/	$32,143,164	190,721	0.32%	Shares
MORGAN STANLEY	$32,058,612	190,219	0.32%	Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$31,213,608	185,200	0.31%	Put option
FULLER & THALER ASSET MANAGEMENT, INC.	$30,192,001	179,149	0.30%	Shares
PRUDENTIAL FINANCIAL INC	$29,909,064	177,465	0.30%	Shares
SEB Asset Management AB	$29,789,208	176,754	0.30%	Shares
Ensign Peak Advisors, Inc	$29,653,059	175,946	0.29%	Shares
IEQ CAPITAL, LLC	$29,628,432	175,800	0.29%	Shares
MACKENZIE FINANCIAL CORP	$29,609,071	175,685	0.29%	Shares
NEW YORK STATE COMMON RETIREMENT FUND	$29,573,511	175,474	0.29%	Shares
Korea Investment CORP	$29,154,701	172,989	0.29%	Shares
PKO BP BANKOWY Universal Pension Society JSC	$28,786,115	170,802	0.29%	Shares
Zurich Insurance Group Ltd/FI	$28,618,254	169,806	0.28%	Shares
Impax Asset Management Group plc	$26,965,600	160,000	0.27%	Shares
Nearwater Capital Markets, Ltd	$26,122,925	155,000	0.26%	Shares
Mariner, LLC	$25,627,342	152,055	0.25%	Shares
Integral Health Asset Management, LLC	$25,281,000	150,000	0.25%	Shares
Rock Springs Capital Management LP	$24,395,441	144,750	0.24%	Shares
Zurcher Kantonalbank (Zurich Cantonalbank)	$23,738,829	140,854	0.24%	Shares
Fisher Asset Management, LLC	$22,769,751	135,104	0.23%	Shares
Aware Super Pty Ltd as trustee of Aware Super	$22,056,175	130,870	0.22%	Shares
RAYMOND JAMES FINANCIAL INC	$22,009,323	130,592	0.22%	Shares
Hudson Bay Capital Management LP	$21,909,550	130,000	0.22%	Shares
Life Cycle Investment Partners Ltd	$21,287,319	126,308	0.21%	Shares
VIRGINIA RETIREMENT SYSTEMS ET Al	$20,937,370	147,623	0.21%	Shares
DNB Asset Management AS	$20,280,996	120,337	0.20%	Shares
JANE STREET GROUP, LLC	$20,072,518	119,100	0.20%	Put option
Sarissa Capital Management LP	$19,639,889	116,533	0.19%	Shares
Andra AP-fonden	$19,522,682	148,191	0.19%	Shares
AMERICAN CENTURY COMPANIES INC	$19,061,140	113,099	0.19%	Shares
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main	$18,885,863	112,059	0.19%	Shares
Man Group plc	$18,859,404	111,902	0.19%	Shares
Mitsubishi UFJ Asset Management Co., Ltd.	$18,788,956	111,484	0.19%	Shares
UBS Group AG	$18,243,577	108,248	0.18%	Shares
Robeco Institutional Asset Management B.V.	$18,197,736	107,976	0.18%	Shares
LOOMIS SAYLES & CO L P	$18,108,412	107,446	0.18%	Shares
Retirement Systems of Alabama	$17,527,134	103,997	0.17%	Shares
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	$17,474,389	132,643	0.17%	Shares
ING GROEP NV	$17,224,277	102,200	0.17%	Shares
Legal & General Group Plc	$17,176,748	101,918	0.17%	Shares
RICE HALL JAMES & ASSOCIATES, LLC	$16,886,364	100,195	0.17%	Shares
Universal- Beteiligungs- und Servicegesellschaft mbH	$16,827,572	99,912	0.17%	Shares
CWM, LLC	$16,696,728	126,740	0.17%	Shares
CAPITAL FUND MANAGEMENT S.A.	$16,536,148	98,117	0.16%	Shares
Clark Capital Management Group, Inc.	$15,629,612	92,738	0.15%	Shares
Distillate Capital Partners LLC	$15,604,993	92,592	0.15%	Shares
LAZARD ASSET MANAGEMENT LLC	$15,399,211	91,371	0.15%	Shares

Company insiders 42 insiders · 21 officers · 15 directors

Insider	Role	Last activity	Shares owned	Sells 12m	Net 12m
Kyle Gano	Chief Executive Officer	Feb. 13, 2025 M	139,907	0	$0
Matt Abernethy	Chief Financial Officer	Feb. 13, 2025 M	35,810	0	$0
Timothy Coughlin	Chief Financial Officer	Feb. 6, 2017 S	137,961	0	$0
David-Alexandre C Gros	President & COO	Feb. 6, 2017 A	—	0	$0
Ingrid Delaet	Chief Regulatory Officer	July 10, 2026 M	16,225	5	$-3,747,962
Darin Lippoldt	Chief Legal Officer	July 9, 2026 M	54,729	4	$-3,497,443
Sanjay Chandru Keswani	Chief Medical Officer	June 2, 2026 F	1,479	0	$0
Julie Cooke	Chief Human Resources Officer	June 2, 2026 M	22,374	1	$-2,200,685
David W. Boyer	Chief Corp. Affairs Officer	Feb. 13, 2025 M	3,565	0	$0
Eiry Roberts	Chief Medical Officer	Feb. 13, 2025 M	35,640	0	$0
Eric Benevich	Chief Commercial Officer	Feb. 13, 2025 M	44,689	0	$0
Malcolm Lloyd-Smith	Chief Integration Officer	Feb. 8, 2023 S	42,337	0	$0
Dimitri E. Grigoriadis	Chief Research Officer	Jan. 31, 2022 A	82,273	0	$0
Haig P. Bozigian	Chief Development Officer	Feb. 8, 2021 A	157,651	0	$0
Christopher Flint Obrien	Former Chief Medical Officer	Feb. 5, 2018 A	55,946	0	$0
VALEUR JENSEN MARGARET E	EVP and General Counsel	Aug. 31, 2011 A	118,256	0	$0
Richard J Ranieri	Sr. VP, Human Resources	Feb. 27, 2008 A	9,667	0	$0
Wendall Wierenga	EVP, Research & Development	Jan. 19, 2006 A	5,023	0	$0
Henry Pan	Executive VP and CMO	June 3, 2005 A	11,216	0	$0
Robert J Little	SVP, Commercial Operations	Feb. 18, 2005 A	—	0	$0
SAUNDERS JOHN	Vice President Research (Chem)	Dec. 18, 2003 S	7,966	0	$0
Leslie V Norwalk	Director	July 29, 2026 M	2,430	2	$-437,584
SHERWIN STEPHEN A	Director	June 5, 2026 M	15,860	5	$-4,132,990
William H Rastetter	Director	May 27, 2026 A	43,678	1	$-2,732,760
Kevin Charles Gorman	Director	May 27, 2026 A	511,293	1	$-37,824,431
Christine A Poon	Director	May 27, 2026 A	4,753	0	$0
POPS RICHARD F	Director	May 27, 2026 A	37,798	1	$-2,364,750
LYONS GARY A	Director	May 27, 2026 A	122,141	1	$-2,289,150
MORROW GEORGE J	Director	May 27, 2026 A	10,386	1	$-2,150,550
Johanna Mercier	Director	May 22, 2025 M	3,535	0	$0
Alfred Sandrock	Director	May 22, 2019 A	—	0	$0
Corinne H Nevinny	Director	May 24, 2018 A	43,283	0	$0
Thomas W Mitchell	Director	May 28, 2015 A	1,000	0	$0
VALE WYLIE W	Director	May 25, 2011 A	231,372	0	$0
Adrian Adams	Director	June 30, 2006 A	—	0	$0
NEUROCRINE BIOSCIENCES INC	10% owner	Feb. 23, 2023 P	8,575,316	0	$0
Jude Onyia	—	Aug. 4, 2026 G	20,996	1	$-1,762,710
Shalini Sharp	—	May 27, 2026 A	4,088	0	$0
MOLLICA JOSEPH A	—	May 22, 2017 A	56,042	0	$0
HAWRAN PAUL W	—	Sept. 18, 2006 J	132,000	0	$0
Lawrence Steinman	—	March 2, 2005 S	15,500	0	$0
CONLON PAUL J	—	Dec. 16, 2003 S	57,335	0	$0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 1 position

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer	Filed	Stake	Status	Purpose	Filing
Neurocrine Biosciences, Inc. ×3 filings	Feb. 24, 2023	—	Initial filing	—	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 129 ETFs

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund	Weight	Units	As of	Source
IBRN · iShares Trust	3.71%	1,793 SH	Aug. 8, 2026	Daily
PBE · Invesco Exchange-Traded Fund Trust	2.51%	55,704 SH	Aug. 8, 2026	Daily
MCOW · Pacer Funds Trust	2.17%	162 NS	April 30, 2026	N-PORT
FGSI · First Trust Exchange-Traded Fund IV	2.01%	457 NS	April 30, 2026	N-PORT
POWA · Invesco Exchange-Traded Self-Indexe…	1.97%	22,094 SH	Aug. 8, 2026	Daily
SMRI · EA Series Trust	1.95%	79,947 NS	April 30, 2026	N-PORT
GRPM · Invesco Exchange-Traded Fund Trust	1.78%	55,458 SH	Aug. 8, 2026	Daily
XMHQ · Invesco Exchange-Traded Fund Trust	1.74%	599,955 SH	Aug. 8, 2026	Daily
BUL · Pacer Funds Trust	1.66%	16,032 NS	April 30, 2026	N-PORT
BBP · ETFis Series Trust I	1.38%	6,192 NS	April 30, 2026	N-PORT
ILDR · First Trust Exchange-Traded Fund VI…	1.29%	23,318 NS	May 31, 2026	N-PORT
IBB · iShares Trust	1.22%	725,434 SH	Aug. 8, 2026	Daily
RFG · Invesco Exchange-Traded Fund Trust	1.16%	25,502 SH	Aug. 8, 2026	Daily
AGNG · Global X Funds	1.12%	5,792 NS	May 31, 2026	N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust …	1.12%	5,472 SH	Aug. 8, 2026	Daily
LABU · Direxion Shares ETF Trust	0.95%	37,476 NS	April 30, 2026	N-PORT
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU…	0.93%	7,516 NS	April 30, 2026	N-PORT
IVOG · VANGUARD ADMIRAL FUNDS	0.89%	99,214 SH	Aug. 8, 2026	Daily
FXH · First Trust Exchange-Traded AlphaDE…	0.87%	57,454 NS	April 30, 2026	N-PORT
IJK · iShares Trust	0.86%	588,275 SH	Aug. 8, 2026	Daily
COWG · Pacer Funds Trust	0.81%	132,963 NS	April 30, 2026	N-PORT
BIB · ProShares Trust	0.80%	3,712 NS	May 31, 2026	N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust …	0.79%	57,321 SH	Aug. 8, 2026	Daily
TMFX · RBB Fund, Inc.	0.76%	1,542 NS	May 31, 2026	N-PORT
ABOT · Abacus FCF ETF Trust	0.72%	240 NS	April 30, 2026	N-PORT
CLSE · Trust for Professional Managers	0.66%	25,529 NS	May 31, 2026	N-PORT
MIDE · DBX ETF Trust	0.64%	136 NS	May 29, 2026	N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr…	0.63%	533 NS	April 30, 2026	N-PORT
IQSM · New York Life Investments ETF Trust	0.55%	13,166 NS	April 30, 2026	N-PORT
SMDX · Tidal Trust III	0.55%	5,215 NS	April 30, 2026	N-PORT
XJH · iShares Trust	0.51%	13,589 SH	Aug. 8, 2026	Daily
ISCG · iShares Trust	0.50%	31,557 SH	Aug. 8, 2026	Daily
QVMM · Invesco Exchange-Traded Fund Trust …	0.49%	13,131 SH	Aug. 8, 2026	Daily
VBK · VANGUARD INDEX FUNDS	0.46%	1,331,820 SH	Aug. 8, 2026	Daily
IVOO · VANGUARD ADMIRAL FUNDS	0.46%	162,408 SH	Aug. 8, 2026	Daily
QLV · FlexShares Trust	0.46%	5,915 NS	April 30, 2026	N-PORT
IJH · iShares Trust	0.44%	3,469,295 SH	Aug. 8, 2026	Daily
SDG · iShares Trust	0.42%	4,563 SH	Aug. 8, 2026	Daily
FNY · First Trust Exchange-Traded AlphaDE…	0.40%	15,614 NS	April 30, 2026	N-PORT
IWP · iShares Trust	0.39%	493,090 SH	Aug. 8, 2026	Daily
PTMC · Pacer Funds Trust	0.39%	11,519 NS	April 30, 2026	N-PORT
USMV · iShares Trust	0.35%	534,448 SH	Aug. 8, 2026	Daily
MVV · ProShares Trust	0.34%	3,468 NS	May 31, 2026	N-PORT
SXQG · EXCHANGE TRADED CONCEPTS TRUST	0.34%	1,461 NS	May 31, 2026	N-PORT
BKMC · BNY Mellon ETF Trust	0.34%	16,076 NS	April 30, 2026	N-PORT
SCHM · SCHWAB STRATEGIC TRUST	0.29%	271,303 NS	May 31, 2026	N-PORT
MIDU · Direxion Shares ETF Trust	0.26%	1,662 NS	April 30, 2026	N-PORT
BBMC · J.P. Morgan Exchange-Traded Fund Tr…	0.26%	40,014 NS	April 30, 2026	N-PORT
IYH · iShares Trust	0.26%	59,243 SH	Aug. 8, 2026	Daily
ISCB · iShares Trust	0.25%	4,488 SH	Aug. 8, 2026	Daily
FSMD · FIDELITY COVINGTON TRUST	0.25%	44,691 NS	April 30, 2026	N-PORT
UMDD · ProShares Trust	0.24%	484 NS	May 31, 2026	N-PORT
VHT · VANGUARD WORLD FUND	0.24%	286,599 SH	Aug. 8, 2026	Daily
JPME · J.P. Morgan Exchange-Traded Fund Tr…	0.23%	7,607 NS	April 30, 2026	N-PORT
FHLC · FIDELITY COVINGTON TRUST	0.21%	45,968 NS	April 30, 2026	N-PORT
SMMD · iShares Trust	0.21%	49,368 SH	Aug. 8, 2026	Daily
VB · VANGUARD INDEX FUNDS	0.20%	2,306,077 SH	Aug. 8, 2026	Daily
SIZE · iShares Trust	0.19%	5,299 SH	Aug. 8, 2026	Daily
VXF · VANGUARD INDEX FUNDS	0.19%	1,153,763 SH	Aug. 8, 2026	Daily
EUSA · iShares, Inc.	0.18%	22,084 SH	Aug. 8, 2026	Daily
ACWV · iShares, Inc.	0.18%	37,215 SH	Aug. 8, 2026	Daily
AVMC · AMERICAN CENTURY ETF TRUST	0.18%	4,529 NS	May 31, 2026	N-PORT
AVIE · AMERICAN CENTURY ETF TRUST	0.17%	108 NS	May 31, 2026	N-PORT
FNDA · SCHWAB STRATEGIC TRUST	0.16%	89,904 NS	May 31, 2026	N-PORT
FNX · First Trust Exchange-Traded AlphaDE…	0.14%	13,779 NS	April 30, 2026	N-PORT
RWK · Invesco Exchange-Traded Fund Trust …	0.12%	10,292 SH	Aug. 8, 2026	Daily
DEUS · DBX ETF Trust	0.12%	2,125 NS	May 29, 2026	N-PORT
FAD · First Trust Exchange-Traded AlphaDE…	0.12%	4,295 NS	April 30, 2026	N-PORT
IWR · iShares Trust	0.11%	403,356 SH	Aug. 8, 2026	Daily
EQAL · Invesco Exchange-Traded Fund Trust …	0.09%	4,673 SH	Aug. 8, 2026	Daily
AFMC · First Trust Exchange-Traded Fund VI…	0.09%	906 NS	May 31, 2026	N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr…	0.09%	209 NS	April 30, 2026	N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS	0.08%	3,864 NS	May 31, 2026	N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe…	0.08%	23,944 SH	Aug. 8, 2026	Daily
LRND · New York Life Investments ETF Trust	0.08%	1,694 NS	April 30, 2026	N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr…	0.07%	20,990 NS	April 30, 2026	N-PORT
DFUV · Dimensional ETF Trust	0.06%	70,547 NS	April 30, 2026	N-PORT
USXF · iShares Trust	0.06%	5,561 SH	Aug. 8, 2026	Daily
SCHG · SCHWAB STRATEGIC TRUST	0.06%	212,211 NS	May 31, 2026	N-PORT
DYNF · BlackRock ETF Trust	0.05%	137,275 SH	Aug. 8, 2026	Daily
GGUS · Goldman Sachs ETF Trust	0.05%	1,464 NS	May 31, 2026	N-PORT
NBCR · Neuberger Berman ETF Trust	0.05%	2,533 NS	May 31, 2026	N-PORT
IUSG · iShares Trust	0.04%	89,104 SH	Aug. 8, 2026	Daily
IWF · iShares Trust	0.04%	321,269 SH	Aug. 8, 2026	Daily
DFAC · Dimensional ETF Trust	0.04%	135,667 NS	April 30, 2026	N-PORT
VONG · VANGUARD SCOTTSDALE FUNDS	0.04%	134,662 SH	Aug. 8, 2026	Daily
GARP · iShares Trust	0.04%	6,947 SH	Aug. 8, 2026	Daily
AVSU · AMERICAN CENTURY ETF TRUST	0.03%	976 NS	May 31, 2026	N-PORT
ONEQ · Fidelity Commonwealth Trust	0.03%	22,757 NS	May 31, 2026	N-PORT
DXUV · Dimensional ETF Trust	0.03%	996 NS	April 30, 2026	N-PORT
QARP · DBX ETF Trust	0.03%	153 NS	May 29, 2026	N-PORT
DCOR · Dimensional ETF Trust	0.03%	7,255 NS	April 30, 2026	N-PORT
AVLC · AMERICAN CENTURY ETF TRUST	0.03%	2,525 NS	May 31, 2026	N-PORT
ESGV · VANGUARD WORLD FUND	0.03%	22,375 SH	Aug. 8, 2026	Daily
TILT · FlexShares Trust	0.02%	3,696 NS	April 30, 2026	N-PORT
PBUS · Invesco Exchange-Traded Fund Trust …	0.02%	16,869 SH	Aug. 8, 2026	Daily
SCHX · SCHWAB STRATEGIC TRUST	0.02%	106,485 NS	May 31, 2026	N-PORT
IYY · iShares Trust	0.02%	4,355 SH	Aug. 8, 2026	Daily
SCHK · SCHWAB STRATEGIC TRUST	0.02%	8,207 NS	May 31, 2026	N-PORT
DFAU · Dimensional ETF Trust	0.02%	19,654 NS	April 30, 2026	N-PORT
GUSA · Goldman Sachs ETF Trust II	0.02%	3,359 NS	May 31, 2026	N-PORT
IWB · iShares Trust	0.02%	68,720 SH	Aug. 8, 2026	Daily
AVUS · AMERICAN CENTURY ETF TRUST	0.02%	18,542 NS	May 31, 2026	N-PORT
SCHB · SCHWAB STRATEGIC TRUST	0.02%	59,421 NS	May 31, 2026	N-PORT
ITOT · iShares Trust	0.02%	131,079 SH	Aug. 8, 2026	Daily
EBI · RBB Fund Trust	0.02%	886 NS	May 31, 2026	N-PORT
IWV · iShares Trust	0.02%	26,722 SH	Aug. 8, 2026	Daily
IWS · iShares Trust	0.02%	20,750 SH	Aug. 8, 2026	Daily
VTI · VANGUARD INDEX FUNDS	0.02%	3,193,839 SH	Aug. 8, 2026	Daily
VONE · VANGUARD SCOTTSDALE FUNDS	0.02%	16,227 SH	Aug. 8, 2026	Daily
VTHR · VANGUARD SCOTTSDALE FUNDS	0.02%	8,342 SH	Aug. 8, 2026	Daily
DFUS · Dimensional ETF Trust	0.02%	30,080 NS	April 30, 2026	N-PORT
RECS · Columbia ETF Trust I	0.02%	7,991 NS	April 30, 2026	N-PORT
PRF · Invesco Exchange-Traded Fund Trust	0.02%	10,869 SH	Aug. 8, 2026	Daily
KOKU · DBX ETF Trust	0.02%	889 NS	May 29, 2026	N-PORT
TOK · iShares Trust	0.02%	265 SH	Aug. 8, 2026	Daily
URTH · iShares, Inc.	0.02%	8,464 SH	Aug. 8, 2026	Daily
MSLC · MORGAN STANLEY PATHWAY FUNDS	0.02%	3,922 NS	May 31, 2026	N-PORT
ACWI · iShares Trust	0.01%	30,548 SH	Aug. 8, 2026	Daily
FNDB · SCHWAB STRATEGIC TRUST	0.01%	938 NS	May 31, 2026	N-PORT
AVMV · AMERICAN CENTURY ETF TRUST	0.01%	441 NS	May 31, 2026	N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX…	0.01%	85,082 SH	Aug. 8, 2026	Daily
VONV · VANGUARD SCOTTSDALE FUNDS	0.01%	8,319 SH	Aug. 8, 2026	Daily
DFVX · Dimensional ETF Trust	0.01%	323 NS	April 30, 2026	N-PORT
GVUS · Goldman Sachs ETF Trust	0.01%	161 NS	May 31, 2026	N-PORT
IWD · iShares Trust	0.01%	30,592 SH	Aug. 8, 2026	Daily
DFAS · Dimensional ETF Trust	0.01%	6,168 NS	April 30, 2026	N-PORT
AVUQ · AMERICAN CENTURY ETF TRUST	0.01%	82 NS	May 31, 2026	N-PORT
REVS · Columbia ETF Trust I	0.01%	108 NS	April 30, 2026	N-PORT

About Neurocrine Biosciences, Inc. - Common Stock Company overview from Wikipedia

History

Product pipeline

NBIX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

NBIX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

Moving averages & overlays

Volume

Oscillators

Momentum & trend

10-Year Performance Revenue, net income, margins and EPS trends

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Financial Health Debt, liquidity, solvency — balance sheet strength

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

NBIX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

12-Month Price Target

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Latest News Recent headlines mentioning this company

Trading Signals Recent buy/sell signals with entry price and risk/reward ratio

My Metrics Your personal watchlist — selected rows from Full Fundamentals

Institutional owners (13F) 827 filers · $10.1B total · As of June 30, 2026

Company insiders 42 insiders · 21 officers · 15 directors

Activists & 5%+ owners 1 position

ETF ownership Held by 129 ETFs